Breathing life into the treatment of respiratory disease

Verona Pharma is developing novel treatments to enhance the lives of those affected by chronic lung conditions.

November is COPD Awareness Month and World COPD Day is November 20th. Verona Pharma is raising awareness of this serious unmet need. Find out more about COPD support groups here.

Science

Innovative therapeutics

Our first product is now approved by the US FDA and we continue to develop our pipeline of novel respiratory therapeutics.

COPD

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition without a cure. It damages the airways and lungs, leading to debilitating breathlessness.

Non-CF Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis (NCFBE) is a chronic lung disease with no FDA-approved treatment. Patients suffer from persistent cough, excess sputum production and frequent respiratory infections.

Cystic Fibrosis

Cystic fibrosis (CF) is a fatal genetic disease characterized by the build-up of thick, sticky mucus and infection that can damage many of the body’s organs.

Asthma

Asthma is a common chronic inflammatory disease that makes it harder to move air in and out of the lungs.

COPD

Non-CF Bronchiectasis

Cystic Fibrosis

Asthma

Patients

Empowering respiratory patients

Understanding the impact of chronic respiratory conditions on patients’ daily lives is vital to improving care.

Empowering respiratory patients

Company

Novel Therapeutics

We’re a biopharmaceutical company focused on developing and commercializing innovative prescription medicines.

Novel Therapeutics

Developing novel therapeutics for respiratory diseases

To learn more about Verona Pharma, please get in touch.